Phil joined Oxford Science Enterprises in September 2021. He works in the Life Sciences Team to identify opportunities, support new company creation and early operations.
Phil joined OSE from MacrophOx, a cell therapy company he co-founded during his post-doctoral research at the University of Oxford, where he served as Chief Technology Officer (and interim CEO) for 3 years.
Phil has a B.Sc. in Biochemistry from Imperial College London and a D.Phil. in Immunotherapy from the University of Oxford.